JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression.
about
MYC Deregulation in Primary Human Cancers.Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm.Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F.Frequency of JAK2 V617F mutation in patients with Philadelphia positive Chronic Myeloid Leukemia in Pakistan.
P2860
JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression.
@en
JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression.
@nl
type
label
JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression.
@en
JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression.
@nl
prefLabel
JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression.
@en
JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression.
@nl
P2093
P356
P1476
JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression.
@en
P2093
Masood Ahmad
Mehwesh Taj
Muhammad Nadeem
Saqib H Ansari
Tahir S Shamsi
Tasneem Farzana
Zaen-Al-Abideen Pahore
P304
P356
08.2011/JCPSP.472475
P577
2011-08-01T00:00:00Z